Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Evaluación de SPN-812 (cápsula de liberación prolongada de viloxazina) en niños en edad preescolar con TDAH

2 de octubre de 2026 actualizado por: Supernus Pharmaceuticals, Inc.

Estudio de fase 4, aleatorizado, doble ciego, multicéntrico, controlado con placebo, de grupos paralelos sobre la eficacia y seguridad de SPN-812 en niños en edad preescolar (4 a 5 años) con trastorno por déficit de atención/hiperactividad (TDAH) )

This study will evaluate the efficacy and safety of SPN-812 (viloxazine extended release) in children 4 to 5 years of age with ADHD.

Descripción general del estudio

Estado

Reclutamiento

Intervención / Tratamiento

Descripción detallada

This is a randomized, double-blind, placebo-controlled, multicenter, 2-arm (1:1), parallel-group, efficacy and safety/tolerability fixed-dose study of SPN-812 in preschool-age children (4 to 5 years old) with ADHD. Participants will be screened for eligibility for up to 4 weeks. Eligible participants will be treated with study medication for 6 weeks. The total duration of the study is up to 10 weeks.

Tipo de estudio

Intervencionista

Inscripción (Estimado)

286

Fase

  • Fase 4

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

Ubicaciones de estudio

    • Alabama
      • Saraland, Alabama, Estados Unidos, 36571
    • Arkansas
      • Fayetteville, Arkansas, Estados Unidos, 72703
        • Retirado
        • Preferred Research Partners-NWA, LLC
      • Little Rock, Arkansas, Estados Unidos, 72211
    • California
      • Anaheim, California, Estados Unidos, 92805
        • Reclutamiento
        • Advanced Research Center (ARC), Inc.
        • Contacto:
      • Encino, California, Estados Unidos, 91316
        • Retirado
        • Wake Research-Pharmacology Research Institute (WR-PRI), LLC [Encino]
      • Garden Grove, California, Estados Unidos, 92844
        • Terminado
        • National Institute of Clinical Research (PICR)
      • Imperial, California, Estados Unidos, 92251
        • Reclutamiento
        • Sun Valley Research Center
        • Contacto:
      • Long Beach, California, Estados Unidos, 90807
        • Reclutamiento
        • Alliance Research
        • Contacto:
      • Newport Beach, California, Estados Unidos, 92660
        • Retirado
        • Wake Research-Pharmacology Research Institute (WR-PRI), LLC [Newport Beach]
    • Colorado
      • Centennial, Colorado, Estados Unidos, 80112
        • Reclutamiento
        • IMMUNOe Research Centers
        • Contacto:
        • Contacto:
          • Número de teléfono: 303-773-9000
    • Florida
      • Clermont, Florida, Estados Unidos, 34711
        • Retirado
        • Vertex Clinical Research, LLC
      • Coral Gables, Florida, Estados Unidos, 33134
        • Reclutamiento
        • Luna Research Center
        • Contacto:
          • Número de teléfono: 305-613-7761
      • Gainesville, Florida, Estados Unidos, 32607
        • Terminado
        • Sarkis Clinical Trials
      • Jacksonville, Florida, Estados Unidos, 32256
        • Reclutamiento
        • Clinical Neuroscience Solutions, Inc.
        • Contacto:
          • Número de teléfono: 904-281-5757
      • Lakeland, Florida, Estados Unidos, 33803
        • Terminado
        • Accel Research Sites - Lakeland CRU
      • Miami, Florida, Estados Unidos, 33155
      • Orange City, Florida, Estados Unidos, 32763
        • Reclutamiento
        • Medical Research Group of Central Florida
        • Contacto:
          • Número de teléfono: 386-775-7627
      • Orlando, Florida, Estados Unidos, 32801
        • Reclutamiento
        • Clinical Neuroscience Solutions, Inc.
        • Contacto:
      • Orlando, Florida, Estados Unidos, 32803
        • Reclutamiento
        • APG Research LLC
        • Contacto:
        • Contacto:
          • Número de teléfono: 165 407-423-7149
      • Tamarac, Florida, Estados Unidos, 33321
        • Reclutamiento
        • D&H Tamarac Research Center
        • Contacto:
          • Número de teléfono: 786-375-6210
          • Correo electrónico: info@dhnrc.com
      • Virginia Gardens, Florida, Estados Unidos, 33166
      • Winter Park, Florida, Estados Unidos, 32789
    • Georgia
      • Atlanta, Georgia, Estados Unidos, 30328
        • Reclutamiento
        • Clinical Integrative Research Center of Atlanta
        • Contacto:
          • Número de teléfono: 678-705-7341
      • Atlanta, Georgia, Estados Unidos, 30318
        • Reclutamiento
        • Advanced Discovery Research LLC
        • Contacto:
      • Decatur, Georgia, Estados Unidos, 30030
        • Reclutamiento
        • CenExcel iResearch, LLC
        • Contacto:
          • Número de teléfono: 404-537-1281
      • Savannah, Georgia, Estados Unidos, 31405
        • Reclutamiento
        • CenExel iResearch, LLC.
        • Contacto:
          • Número de teléfono: 912-744-0800
    • Indiana
      • Evansville, Indiana, Estados Unidos, 47715
        • Terminado
        • Qualmedica Research, LLC.
    • Kentucky
      • Bardstown, Kentucky, Estados Unidos, 40004
        • Reclutamiento
        • Kentucky Pediatric/Adult Research
        • Contacto:
          • Número de teléfono: 502-349-1569
          • Correo electrónico: kpar@kpar.us
      • Owensboro, Kentucky, Estados Unidos, 42301
        • Terminado
        • Qualmedica Research, LLC.
    • Louisiana
      • New Orleans, Louisiana, Estados Unidos, 70115
        • Terminado
        • DelRicht Research (Touro Medical Center)
      • Prairieville, Louisiana, Estados Unidos, 70769
        • Reclutamiento
        • DelRicht Research
        • Contacto:
    • Maryland
      • Baltimore, Maryland, Estados Unidos, 21205
        • Reclutamiento
        • Kennedy Krieger Institute
        • Contacto:
          • Número de teléfono: 443-923-3850
    • Massachusetts
      • Boston, Massachusetts, Estados Unidos, 02445
        • Reclutamiento
        • Boston Children's Hospital
        • Contacto:
          • Número de teléfono: 617-919-6954
        • Contacto:
    • Michigan
      • Bloomfield Hills, Michigan, Estados Unidos, 48302
        • Reclutamiento
        • Neurobehavioral Medicine Group
        • Contacto:
    • Mississippi
      • Flowood, Mississippi, Estados Unidos, 39232
        • Reclutamiento
        • Precise Research Centers
        • Contacto:
          • Número de teléfono: 601-420-5812
    • Nevada
      • Las Vegas, Nevada, Estados Unidos, 89128
        • Reclutamiento
        • Clinical Research of Southern Nevada, LLC.
        • Contacto:
    • New Jersey
      • Berlin, New Jersey, Estados Unidos, 08009
        • Retirado
        • Hassman Research Institute
      • Irvington, New Jersey, Estados Unidos, 07111
      • Neptune City, New Jersey, Estados Unidos, 07753
        • Reclutamiento
        • Jersey Shore University Medical Center
        • Contacto:
    • New York
      • New York, New York, Estados Unidos, 10028
        • Retirado
        • Icahn School of Medicine at Mount Sinai
    • North Carolina
      • Durham, North Carolina, Estados Unidos, 27705
        • Reclutamiento
        • Duke University
        • Contacto:
          • Número de teléfono: 919-681-1100
    • Ohio
      • Cincinnati, Ohio, Estados Unidos, 45229
        • Reclutamiento
        • Cincinnati Children's Hospital and Medical Center
        • Contacto:
      • West Chester, Ohio, Estados Unidos, 45069
        • Retirado
        • CincyScience
    • Oregon
      • Gresham, Oregon, Estados Unidos, 97030
        • Reclutamiento
        • Cyn3rgy Research
        • Contacto:
    • Pennsylvania
      • Hershey, Pennsylvania, Estados Unidos, 17033
        • Reclutamiento
        • Penn State Health Medical Group - Psychiatry and Behavioral Health
        • Contacto:
        • Contacto:
          • Número de teléfono: 717-531-5656
    • South Carolina
      • North Charleston, South Carolina, Estados Unidos, 29405
      • Summerville, South Carolina, Estados Unidos, 29486
        • Reclutamiento
        • Coastal Pediatric Research
        • Contacto:
    • Tennessee
      • Memphis, Tennessee, Estados Unidos, 38119
        • Reclutamiento
        • Clinical Neuroscience Solutions, Inc.
        • Contacto:
          • Número de teléfono: 901-843-1045
    • Texas
      • Bellaire, Texas, Estados Unidos, 77401
        • Retirado
        • Houston Clinical Trials, LLC.
      • Dallas, Texas, Estados Unidos, 75230
        • Terminado
        • Javara
      • Plano, Texas, Estados Unidos, 75093
        • Reclutamiento
        • AIM Trials, LLC
        • Contacto:
        • Contacto:
          • Número de teléfono: 214-856-2778
      • The Woodlands, Texas, Estados Unidos, 77381
        • Reclutamiento
        • Family Psych of The Woodlands
        • Contacto:
    • Virginia
      • Petersburg, Virginia, Estados Unidos, 23805
      • Richmond, Virginia, Estados Unidos, 23220
        • Reclutamiento
        • Virginia Commonwealth University, Virginia Treatment Center for Children
        • Contacto:
          • Número de teléfono: 804-628-8736

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

4 años a 5 años (Niño)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  1. Is male or female 4 years 0 months of age to less than or equal to 5 years 9 months of age at Visit 1 (Screening) and considered medically healthy.
  2. Subject's parent(s) or legal guardian(s)/representative(s) is (are) willing and able to provide written informed consent before completing any study related procedures.
  3. Has a primary diagnosis of ADHD according to DSM-IV-TR criteria and confirmed with the Kiddie Schedule for Affective Disorders and Schizophrenia - Present and Lifetime Version (K-SADS-PL).
  4. Has an ADHD-RS-IV-P Total Score of ≥ 28 (males) or ≥ 24 (females) at Visit 1 (Screening) and at Visit 2 (Baseline).
  5. Has a CGI-S score of ≥ 4 (moderate or worse) at Visit 1 (Screening) and at Visit 2 (Baseline).
  6. Has undergone an adequate course of non-pharmacologic treatment or is having symptoms severe enough to warrant pharmacologic treatment without prior non-pharmacologic treatment.
  7. Is participating in a structured group activity (e.g., preschool, kindergarten, sports, Sunday school, summer camp or childcare program) at least 2 days a week during study so as to assess symptoms and impairment in a setting outside the home.
  8. Has not initiated any behavioral intervention/therapy within 30 days of Visit 1 (Screening) and does not plan to initiate any new or discontinue any ongoing behavioral intervention/therapy during the study (e.g., subject is eligible if behavioral intervention/therapy is initiated 30 or more days prior to Visit 1 [Screening] and continues with a similar duration/frequency throughout their study).
  9. Subjects who are on ADHD medication at Visit 1 (Screening), but whose ADHD symptoms are not well controlled on current ADHD medication (e.g., meets Inclusion Criterion #4), meet all other inclusion/exclusion criteria, and discontinues ADHD medication at least 7 days prior to the day of Visit 2 (Baseline) are eligible to participate.
  10. Has no current condition in the opinion of the Investigator that could confound efficacy assessments, safety assessments or increase participant risk.
  11. Has lived with the same parent(s) or legal guardian(s) or has lived under a shared living arrangement (e.g., joint legal custody) for greater than or equal to 6 months prior to Visit 1 (Screening).
  12. Has a body weight ≥5th percentile for age and sex at Visit 1 (Screening) and Visit 2 (Baseline).

Exclusion Criteria:

  1. Has a diagnosis at Screening (per K-SADS-PL) of another psychiatric disorder that is considered to be the primary diagnosis rather than ADHD or has a comorbid psychiatric disorder secondary to ADHD that, in the opinion of the investigator (after consulting medical monitor), will likely interfere with study treatment adherence and/or impact study results.
  2. Has a current diagnosis of a major neurological disorder. The eligibility of those who have seizures, a history of seizure-like events (e.g., syncope, myoclonus, severe muscle spasms), a family history of seizure disorder (immediate family, i.e., sibling, parent), and/or febrile seizures will be assessed on a case-by-case basis after consulting the medical monitor.
  3. History of Bipolar Disorder diagnosed in a first degree relative.
  4. Has global development delay or intellectual disability by medical history.
  5. Has a current diagnosis of a significant (per Investigator's evaluation and/or judgement) systemic disease.
  6. Has body mass index > 95th percentile for the subject's age and sex at Visit 1 (Screening) or Visit 2 (Baseline).
  7. Has a mean resting systolic and diastolic blood pressure* that are both >95th percentile for age sex, and height and has a mean resting pulse rate* that is >95th percentile for age and sex (males: >117 bpm; females: >122 bpm) at Visit 1 (Screening) or Visit 2 (Baseline). * Note: The mean of three measurements while seated.
  8. Has a clinically significant electrocardiogram finding(s) at Visit 1 (Screening).
  9. Is currently taking SPN-812 for ADHD, has previously taken SPN-812 for ADHD, but discontinued due to a lack of efficacy or adverse reactions, or has history of allergic reaction, hypersensitivity or intolerance to viloxazine.
  10. Has an allergy to or cannot swallow pudding and applesauce and cannot swallow intact capsule whole.
  11. Has any food allergy, intolerance, restriction or special diet that, in the opinion of the Investigator, could contraindicate the subject's participation in the study.
  12. Has received any investigational drug within the longer of 30 days or 5 half-lives prior to Visit 2 (e.g., first dose of study medication).
  13. Has a positive urine drug test at Visit 1 (Screening). A positive test for amphetamines is allowed for subjects receiving a stimulant ADHD medication at Screening. The subject will be required to discontinue the stimulant for the duration of the study, beginning at least 7 days prior to Visit 2 (Baseline).
  14. Is using of prohibited concomitant medications including known CYP1A2 substrates (e.g., theophylline, melatonin) during the Screening Period or (anticipated) for the duration of the study.
  15. Any reason that, in the opinion of the Investigator, would prevent the subject from participating in the study.
  16. Has suicidal ideation ("Yes" indicated on C-SSRS question 4 or 5) or suicidal behavior ("Yes" indicated on C-SSRS for any suicidal behavior) within 6 months prior to or the day of Visit 1 (Screening) or has attempted suicide ("Yes" indicated on C-SSRS for lifetime).

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Cuadruplicar

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Comparador de placebos: Placebo

Placebo, qd

Placebo will be administered once daily

Experimental: SPN-812

SPN-812, qd

100mg SPN-812 will be administered once daily and compared to Placebo

Otros nombres:
  • SPN-812

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Change from Baseline in the Attention-Deficit/Hyperactivity Disorder Rating Scale, 4th Edition, Preschool Version (ADHD-RS-IV-P) Total Score at End of Study (Week 6)
Periodo de tiempo: Baseline and Week 6

The Attention-Deficit/Hyperactivity Disorder Rating Scale, 4th Edition, Preschool Version (ADHD-RS-IV-P) consists of 18 items that correspond directly to the DSM-IV-TR criteria for ADHD. The scale is subdivided into two subscales: inattention ("IA", 9 items) and hyperactivity-impulsivity ("H/I", 9 items).The clinician rates the frequency and severity of each symptom on a 4-point Likert-type scale, where 0 = Never or rarely, 1 = Sometimes, 2 = Often, and 3 = Very often. The sum of the ratings of all 18 items yields the raw Total score (range: 0-54; the higher the Total score, the more severe the ADHD symptoms). Post-baseline raw Total scores are converted to a change from baseline Total score. A lower change from baseline ADHD-RS-IV-P Total Score (<0) represents a better outcome.

Baseline and Week 6

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Change from Baseline in the Clinical Global Impression of Severity (CGI-S) Score at End of Study (Week 6)
Periodo de tiempo: Baseline and Week 6

The Clinical Global Impression of Severity (CGI-S) is a single item clinician-rated assessment of the severity of subject's condition (ADHD symptoms) in relation to the clinician's total experience with patients with ADHD. The CGI-S is evaluated on a 7-point scale with 1 = Normal, not at all ill, asymptomatic, 2 = Borderline Ill, 3 = Mildly Ill, 4 = Moderately Ill, 5 = Markedly Ill, 6 = Severely Ill, and 7 = Among the most extremely ill patients (the higher the score, the more severe the overall ADHD symptoms). Post-baseline (raw) CGI-S scores are converted to a change from baseline score. A lower change from baseline CGI-S score (<0) represents a better outcome.

Baseline and Week 6
Clinical Global Impression of Change (CGI-C) Score at End of Study (Week 6)
Periodo de tiempo: Week 6

The Clinical Global Impression of Change (CGI-C) is a single item clinician-rated assessment of how much the subject's condition (ADHD) has improved, worsened or has not changed relative to his/her baseline state prior to the beginning of treatment. The CGI-C is rated on a 7-point scale from 1 to 7, where 1 = "very much improved", 2 = "much improved", 3 = "minimally improved", 4 = "no change", 5 = "minimally worse", 6 = "much worse", and 7 = "very much worse". A CGI-C score <4 represents a better outcome.

Week 6
Change from Baseline in Attention-Deficit/Hyperactivity Disorder Rating Scale, 4th Edition, Preschool Version (ADHD-RS-IV-P) Hyperactivity/Impulsivity Subscale Score at End of Study (Week 6)
Periodo de tiempo: Baseline and Week 6

The Attention-Deficit/Hyperactivity Disorder Rating Scale, 4th Edition, Preschool Version (ADHD-RS-IV-P) consists of 18 items that correspond directly to the DSM-IV-TR criteria for ADHD. The scale is subdivided into two subscales: inattention ("IA", 9 items) and hyperactivity-impulsivity ("H/I" 9 items).The clinician rates the frequency and severity of each symptom on a 4-point Likert-type scale, where 0 = Never or rarely, 1 = Sometimes, 2 = Often, and 3 = Very often. The sum of the nine H/I items yields the raw H/I subscale score (range: 0-27; the higher the H/I subscale score, the more severe the H/I symptoms). Post-baseline raw H/I subscale scores are converted to a change from baseline score. A lower change from baseline H/I subscale score (<0) represents a better outcome.

Baseline and Week 6
Change from Baseline in Attention-Deficit/Hyperactivity Disorder Rating Scale, 4th Edition, Preschool Version (ADHD-RS-IV-P) Inattention Subscale Score at End of Study (Week 6)
Periodo de tiempo: Baseline and Week 6

The Attention-Deficit/Hyperactivity Disorder Rating Scale, 4th Edition, Preschool Version (ADHD-RS-IV-P) consists of 18 items that correspond directly to the DSM-IV-TR criteria for ADHD. The scale is subdivided into two subscales: inattention ("IA", 9 items) and hyperactivity-impulsivity ("H/I" 9 items).The clinician rates the frequency and severity of each symptom on a 4-point Likert-type scale, where 0 = Never or rarely, 1 = Sometimes, 2 = Often, and 3 = Very often. The sum of the nine IA items yields the raw IA subscale score (range: 0-27; the higher the IA subscale score, the more severe the IA symptoms). Post-baseline raw IA subscale scores are converted to a change from baseline score. A lower change from baseline IA subscale score (<0) represents a better outcome.

Baseline and Week 6
Clinical Global Impression of Severity (CGI-S) Responder Rate (percentage of subjects with CGI-S score of 1 or 2) at End of Study (Week 6)
Periodo de tiempo: Baseline and Week 6

The Clinical Global Impression of Severity (CGI-S) is a single item clinician-rated assessment of the severity of subject's condition (ADHD symptoms) in relation to the clinician's total experience with patients with ADHD. The CGI-S is evaluated on a 7-point scale with 1 = Normal, not at all ill, asymptomatic, 2 = Borderline Ill, 3 = Mildly Ill, 4 = Moderately Ill, 5 = Markedly Ill, 6 = Severely Ill, and 7 = Among the most extremely ill patients. The responder rate (percent) is calculated by dividing "the number of 'responders' (m)" by "the number of subjects analyzed at the respective Visit/Week (n)" and multiplying the product by 100. Responder Rate values range from 0 to 100%. A percent >50% represents a greater number of "responders" versus "non-responders".

Baseline and Week 6
Clinical Global Impression of Change (CGI-C) Responder Rate (percentage of subjects with CGI-C score of 1 or 2) at End of Study (Week 6)
Periodo de tiempo: Week 6

The Clinical Global Impression of Change (CGI-C) is a single item clinician-rated assessment of how much the subject's condition (ADHD) has improved, worsened or has not changed relative to his/her baseline state prior to the beginning of treatment. The CGI-C is rated on a 7-point scale from 1 to 7, where 1 = "very much improved", 2 = "much improved", 3 = "minimally improved", 4 = "no change", 5 = "minimally worse", 6 = "much worse", and 7 = "very much worse". The responder rate (percent) is calculated by dividing "the number of 'responders' (m)" by "the number of subjects analyzed at the respective Visit/Week (n)" and multiplying the product by 100. Responder Rate values range from 0 to 100%. A percent >50% represents a greater number of "responders" versus "non-responders".

Week 6
Attention-Deficit/Hyperactivity Disorder Rating Scale, 4th Edition, Preschool Version (ADHD-RS-IV-P) Responder Rate (percentage of subjects with ≥ 50% Reduction in Change from Baseline) at End of Study (Week 6)
Periodo de tiempo: Baseline and Week 6

The Attention-Deficit/Hyperactivity Disorder Rating Scale, 4th Edition, Preschool Version (ADHD-RS-IV-P) consists of 18 items that correspond directly to the DSM-IV-TR criteria for ADHD. The scale is subdivided into two 9 item subscales: inattention and hyperactivity-impulsivity. The clinician rates the frequency and severity of each symptom on a 4-point Likert-type scale; 0 = Never or rarely, 1 = Sometimes, 2 = Often, and 3 = Very often. Sum of 18 ratings yields the Total score (range: 0-54; higher score represents severer symptoms). Percent reduction is calculated for the ADHD-RS-IV-P score: [("Post-baseline"-"Baseline")/"Baseline"] x 100; range: 0 to 100%; a "responder" is a subject with a 50% or greater reduction in change from baseline Total score. Responder rate (percent of responders) is calculated: ["number of 'responders' (m)"/ "number of subjects analyzed" (n)] X 100; range: 0 to 100%. A Responder Rate greater than 50%, represents more "responders" versus "nonresponders".

Baseline and Week 6

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Investigadores

  • Director de estudio: Joseph Hull, PhD, Supernus Pharmaceuticals, Inc.

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

19 de marzo de 2024

Finalización primaria (Estimado)

1 de enero de 2028

Finalización del estudio (Estimado)

1 de enero de 2028

Fechas de registro del estudio

Enviado por primera vez

26 de febrero de 2021

Primero enviado que cumplió con los criterios de control de calidad

1 de marzo de 2021

Publicado por primera vez (Actual)

4 de marzo de 2021

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

5 de octubre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

2 de octubre de 2026

Última verificación

1 de octubre de 2026

Más información

Términos relacionados con este estudio

Palabras clave

Otros números de identificación del estudio

  • 812P401

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

Sí

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir